Usefulness of the MSG/IFICG/EORTC diagnostic criteria of invasive pulmonary aspergillosis in the clinical management of patients with acute leukaemia developing pulmonary infiltrates

Ann Hematol. 2007 Mar;86(3):205-10. doi: 10.1007/s00277-006-0204-3. Epub 2006 Nov 21.

Abstract

Invasive pulmonary aspergillosis (IPA) is a frequently fatal complication in patients with acute leukaemia. Because diagnosis is still difficult, non-invasive diagnostic criteria were recently proposed by MSG/IFICG/EORTC for study purposes. We have analysed their usefulness in the clinical management of acute leukaemic patients with pulmonary infiltrates. Twenty-seven infiltrates developed during 174 chemotherapy cycles given to 50 consecutive patients. According to diagnostic criteria, IPA was diagnosed in 42% of patients and 77.8% of pulmonary infiltrates. AML diagnosis and the first induction cycle were significant risk factors. "Proven" IPA was rare, occurring in one patient (2%). The diagnosis of "probable" IPA was made in seven patients (14%) and was strongly supported by the significant association of characteristic radiological lesions ("major" clinical criterion) with the positivity of one microbiological criterion (P = 0.026). Conversely, "possible" IPA was frequent (26%) because its pertinent diagnostic criteria were fulfilled in 48.1% of pulmonary infiltrates. However, in 84.6% of cases, the diagnosis of "possible IPA" aspecifically derived from the association of two conditions, a new pulmonary infiltrate with symptoms of lower respiratory tract infection ("minor clinical criterion"), together with the definition of "susceptible" host, which applied to 100% of our leukaemic patients. We conclude that, according to MSG/IFICG/EORTC criteria, a high number of pulmonary infiltrates would be diagnosed as IPA, but only a diagnosis of "proven/probable" IPA should be considered reliable in the clinical management of suspected IPA.

MeSH terms

  • Acute Disease
  • Adult
  • Aged
  • Antifungal Agents / therapeutic use
  • Aspergillosis, Allergic Bronchopulmonary / diagnosis*
  • Aspergillosis, Allergic Bronchopulmonary / drug therapy*
  • Aspergillosis, Allergic Bronchopulmonary / etiology
  • Ciprofloxacin / therapeutic use
  • Female
  • Humans
  • Itraconazole / therapeutic use
  • Leukemia / complications*
  • Male
  • Middle Aged
  • Models, Theoretical
  • Ofloxacin / therapeutic use
  • Practice Guidelines as Topic*
  • Reproducibility of Results
  • Treatment Outcome

Substances

  • Antifungal Agents
  • Itraconazole
  • Ciprofloxacin
  • Ofloxacin